Clinical Research Directory

General Inclusion Criteria: * ECOG 0-2 * Has a histologically or cytologically confirmed malignancy meeting one of the protocol-defined disease-specific eligibility criteria below: * Part 1: PTCL, CTCL, T-cell LGL, cHL, and DLBCL (non-GCB): Relapsed/refractory disease meeting disease-specific prior treatment requirements. * T-cell LGL: Must also have treatment-requiring anemia and/or neutropenia. * Advanced solid tumors: No standard therapy expected to provide clinical benefit, with or without STAT3 pathway activation. * Part 2: cHL: Relapsed/refractory after brentuximab vedotin and an immune checkpoint inhibitor. * PTCL/CTCL: Relapsed/refractory after ≥1 prior systemic therapy (ALCL requires prior brentuximab vedotin). General Exclusion Criteria: * Prior treatment with a STAT3 degrader (unless permitted in a specific cohort). * Recent stem cell transplant (allogeneic within 90 days; autologous within 60 days), active GvHD, or CAR-T therapy within 30 days. * Use of prohibited medications, including warfarin, QT-prolonging agents, or certain CYP3A/CYP2C8/CYP2C9-interacting drugs. * Active gastrointestinal disease that may affect drug absorption or tolerability (eg, Crohn's disease, ulcerative colitis, peptic ulcer disease, diverticulitis, uncontrolled vomiting, or diarrhea). * Active, untreated, or unstable CNS involvement (brain metastases, leptomeningeal disease, or spinal cord compression). * Clinically significant cardiovascular disease, including recent arterial thrombotic events, uncontrolled hypertension, heart failure, significant ECG abnormalities, prolonged QTc, or reduced LVEF. * Active uncontrolled infection, uncontrolled autoimmune disease, or chronic corticosteroid use \>10 mg/day prednisone equivalent. * Other active malignancies requiring treatment. * Uncontrolled HBV, HCV, or HIV infection not meeting protocol-defined requirements.